Biocon has informed that it has received the Certificate of GMP compliance from EMA for its Biologics Drug Product (DP) as well as Drug Substance (DS) facilities at Biocon Park, Bengaluru. These facilities, used for the manufacture of Biocons portfolio of biosimilars, were inspected by the European agency in March 2019. This was a surveillance inspection of our existing DP and DS facilities and a pre-approval inspection of our additional DP manufacturing line. This certification will enable us to continue addressing the growing needs of patients in the EU markets and enhance access to our high quality biosimilars. We remain committed to global standards of quality and compliance. -Company Spokesperson
The above information is a part of company’s filings submitted to BSE.
